Printer Friendly

USE OF ELAN'S PATCH DOUBLES QUIT RATE AT ONE YEAR

 ATHLONE, Ireland, April 29 /PRNewswire/ -- At the Nicotine Patch Symposium sponsored by Elan Corporation plc (AMEX: ELN) in Athlone today, Professor Kenneth Offord of the Mayo Clinic reported results of the latest clinical trials which are soon to be published by the Clinic. The trials were based on follow up of subjects who had attended the Clinics's Nicotine Dependence Centre and showed that after one year, 27.5 percent of the subjects who used Niconil were still non-smokers as against 14 percent who used a placebo patch.
 The Symposium, which is being attended by over 60 delegates representing Elan's licensees in 25 countries, is part of Elan's program of supporting the companies who market its products worldwide. The conference, which is being chaired by Professor Joseph G. Masterson, is also being addressed by:
 -- Michael C. Fiore, M.D., director, Center for Tobacco Research,
 University of Wisconsin
 -- Dr. Timothy B. Baker, Professor of Psychology, University of
 Wisconsin
 -- John A. Quelch, Professor of Business Administration, Harvard
 University
 -- Dr. Kenneth P. Offord, Associate Professor of Biostatistics, Mayo
 Clinic
 -- Robert Molimard, Professor of Physiology, Faculty of Medicine of
 Paris-Sud


and will discuss a range of topics varying from global marketing to the role of support programs in assisting people to quit smoking.
 Elan further announced that, together with its Elan Transdermal Subsidiary, it had reached an amicable settlement with Cygnus Therapeutic Systems regarding a lawsuit brought by Elan Transdermal and Elan against Cygnus alleging patent infringement by the manufacture and sale of nicotine patches manufactured by Cygnus. Cygnus indicated that the settlement would have no material adverse financial impact upon it.
 Elan Corporation plc is a leader in the specialized health care field of advanced reformulations and drug delivery, concentrating on improved drug absorption and utilization.
 -0- 4/29/93
 /CONTACT: Brian Crotty of Elan Corporation plc, 800-252-3526/
 (ELN)


CO: Elan Corporation plc ST: IN: MTC SU:

WB-TM -- NY115 -- 2900 04/29/93 17:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1993
Words:322
Previous Article:DIME SAVINGS BANK OF NEW YORK MAKES AVAILABLE JOB LOSS MORTGAGE PROTECTION INSURANCE
Next Article:AMERICAN STOCK EXCHANGE DAILY REPORT
Topics:


Related Articles
ELAN TO DOUBLE SIZE OF GAINESVILLE, GA. FACILITY FOR PRODUCTION OF NICOTINE PATCH AND OTHER DRUGS
ELAN'S SMOKING CESSATION PRODUCT -- FIRST OTC LAUNCH
PROSTEP NICOTINE TRANSDERMAL SYSTEM RECEIVES APPROVAL
U.S. FDA APPROVES ELAN'S NICOTINE PATCH
/FIRST ADD -- NY081 -- ELAN'S NICOTINE PATCH APPROVED BY FDA/
ELAN STEPS UP PROSTEP PATCH PRODUCTION FOR CYANAMID'S LEDERLE; MORE THAN FOUR MILLION SHIPPED THUS FAR
COURT RULES IN FAVOR OF CYGNUS MOTION FOR SUMMARY JUDGMENT; DISMISSES IMPORTANT PARTS OF PATENT INFRINGEMENT SUIT
ELAN ADDS $200 MILLION OF NICOTINE PATCH PRODUCTION CAPACITY WITH SECOND UNIT; U.S. MARKET SHARE NOW AT 30 PERCENT
LEDERLE ANNOUNCES PROSTEP NOW FULLY AVAILABLE; NATIONAL ADVERTISING BEGINS ON THE OLYMPICS THIS WEEK
New Aid to Smoking Cessation Treatment Available to Help Smokers Declare Independence from Cigarettes

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters